Systematic Review

Indian J Med Res 148, July 2018, pp 77-89
DOI: 10.4103/ijmr.IJMR_2020_17

A systematic review on association between smokeless tobacco & cardiovascular diseases

Ruchika Gupta¹, Sanjay Gupta¹, Shashi Sharma², Dhirendra N. Sinha³ & Ravi Mehrotra³

¹Division of Cytopathology, ²Division of Epidemiology & Biostatistics, ³WHO FCTC Global Knowledge Hub for Smokeless Tobacco, ICMR-National Institute of Cancer Prevention & Research, Noida & ⁴School of Preventive Oncology, Patna, India

Received December 21, 2017

Background & objectives: The association of smokeless tobacco (SLT) with cardiovascular diseases has remained controversial due to conflicting reports from various countries. Earlier meta-analyses have shown significantly higher risk of fatal myocardial infarction and stroke in SLT users. However, the risk of hypertension (HTN) with SLT products has not been reviewed earlier. This systematic review was undertaken to summarize the evidence available from global literature on the association of SLT with cardiovascular outcomes – heart disease, stroke and HTN.

Methods: A systematic literature search was performed in PubMed and Google Scholar since their inception till October 2017 using pre-decided search terms and inclusion/exclusion criteria. Data were extracted from studies included independently by two authors and reviewed.

Results: The review included 50 studies - 23 on heart disease, 14 on stroke and 14 on HTN. Majority of the studies evaluating heart disease or stroke were conducted in the European Region and most of these did not find a significant association between SLT use and either of these outcomes. On the other hand, 70 per cent of the studies on HTN were reported from South-East Asian Region and about half of the studies found a higher risk of HTN in SLT users.

Interpretation & conclusions: Current available evidence is insufficient to conclusively support the association of cardiovascular diseases with SLT use due to variability in results and methodological constraints in most of the studies. Region and product-specific well-designed studies are required to provide this evidence to the policymakers. However, advice on cessation of SLT products should be offered to patients presenting with cardiovascular diseases.

Key words Cardiovascular - hypertension - myocardial infarction - smokeless tobacco - stroke

Smokeless tobacco (SLT) is a large heterogeneous group of products used either orally or nasally without combustion¹. Over the years, SLT has assumed global epidemic proportions with users in more than 100 countries². The International Agency for Research on Cancer (IARC) has accepted the causative role of SLT products in oral cancer³. However, the linkage of SLT with cardiovascular diseases, i.e., coronary heart disease (CHD)/myocardial infarction (MI)/heart failure, stroke and hypertension (HTN), has not been

77
accepted widely. This is due to the interregion variation in the results available in existing literature, which in turn has been attributed to the differing chemical composition, manufacturing practices and methods of use of products used in various regions. Various studies have demonstrated deep-rooted community perceptions favouring the use of SLT despite evidence supporting the deleterious health effects of these products. A study from Bangladesh showed that SLT was considered to be a remedy for toothache though almost all participants accepted that these products caused heart disease, cancer and tuberculosis. A recent study from Nigeria revealed that SLT users believed it to aid in sleep, protect against cold and act as a cure for headaches, apart from giving a ‘feel of high’.

Earlier meta-analyses have demonstrated a higher risk of fatal CHD and stroke in SLT users, though significant positive association with non-fatal outcome was not demonstrated. These analyses have also highlighted the regional variation in these associations. HTN has been included in a few studies for its association with SLT use. However, the same has not been summarized as yet in the available literature.

Hence, the present systematic review was undertaken to summarize the available updated evidence on the association of SLT use with heart disease, stroke and HTN with a focus on the debate regarding the association between SLT and CHD.

Material & Methods

Literature search was undertaken independently by two experts (RG and SG) who reviewed all publications. In the event of disagreement, discussions were held to reach a consensus regarding the suitability of the publication. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were followed. The inclusion criteria included as follows: (i) Articles published till October 2017 in English language or other languages with summary providing detailed results in English; (ii) Exposure variable: SLT. Studies including both smokers as well as SLT users were considered only if separate results for SLT users were provided; (iii) Outcome variable: cardiovascular disease, CHD or MI or heart failure or stroke or HTN or high blood pressure (BP); and (iv) Study design: case-control, cohort or cross-sectional studies with at least 150 total participants.

Case reports, case studies, letters or reviews were excluded. Studies reporting on cardiovascular risk factors only and not including outcome were also excluded from the study. PubMed and Google Scholar were used as the primary databases for literature search. An initial search yielded 792 articles. In addition, cross-references of all selected publications as well as earlier reviews on this topic were checked for more articles. The search strategy is outlined in Figure.

Results

A total of 50 studies were included in this review (23 with outcome of heart disease, 14 reports on stroke and 14 on HTN).

Smokeless tobacco and heart disease: Of the 23 studies reporting on the risk of heart disease in SLT users (Table I), 11 were conducted in European Region (EUR), three each in American Region (AMR) and Eastern Mediterranean Region (EMR) and five were reported from South-East Asia Region (SEAR). One study, INTERHEART, was multicountry, though the majority of SLT users belonged to SEAR Region.

![Search strategy for epidemiological studies on smokeless tobacco (SLT) and cardiovascular diseases included in systematic review.](image-url)
### Table I. Detailed characteristic of studies on smokeless tobacco (SLT) and heart disease included in the systematic review

| Author/year          | Study design | Sample size | Age of participants (yr) | Gender | Type of SLT | Outcome studied | ORs/RRs (95% CI) | Confounders adjusted |
|----------------------|--------------|-------------|--------------------------|--------|-------------|-----------------|------------------|----------------------|
| **European Region**  |              |             |                          |        |             |                 |                  |                      |
| Huhtasaari et al, 1992 | Case control | Cases 585   | 35-64                    | Men    | Snuff       | Fatal and non-fatal | 0.89 (0.62-1.29) | Age                  |
| Bolinder et al, 1994  | Cohort       | 84,781      | 16-65                    | Men, never-smokers | SLT not specified | Fatal           | 2.0 (1.4-2.9) 35-54 yr 1.20 (1.0-1.5) 55-65 yr | Age, smoking, place of residence |
| Huhtasaari et al, 1999 | Case control | Cases 687   | 25-64                    | Men    | Snuff       | Fatal and non-fatal | 1.50 (0.45-5.03) |                      |
| Hergens et al, 2005   | Case control | Cases 1432  | 45-70                    | Men, never-smokers | Snuff    | Fatal and non-fatal | 1.70 (0.48-5.5) 0.59 (0.25-1.4) | Age, smoking, residence, BMI, physical activity, diabetes, BP, smoking |
| Johansson et al, 2007 | Cohort       | 3120        | 30-74                    | Men, never-smokers | Snuff    | Fatal and non-fatal | 1.41 (0.61-3.28) |                      |
| Hergens et al, 2007   | Cohort       | 118,395     | -                        | Men, never-smokers | Snuff    | Fatal and non-fatal | 0.94 (0.83-1.06) 1.32 (1.08-1.61) 1.96 (1.08-3.58) | Age, smoking, BMI, residence |
| Wennberg et al, 2007  | Case control | Cases 525   | 30-60                    | Men, never-smokers | Snuff    | Fatal and non-fatal | 0.82 (0.46-1.43) 1.18 (0.38-3.70) 1.12 (0.38-3.29) | Age, smoking, BMI, cholesterol, education, physical activity |
| Haglund et al, 2007   | Cohort       | 5002        | 16-74                    | Men    | Snuff       | Fatal and non-fatal | 1.15 (0.54-2.41) 0.77 (0.51-2.41) | Age, smoking, self-reported health, number of long illness, physical activity |
| Hansson et al, 2009   | Cohort       | 16,642 twins| >40                      | Men, never-smokers | Snu      | Fatal and non-fatal | 0.85 (0.51-1.41) | Age, smoking, BP, diabetes, cholesterol |
| Janzon and Hedblad 2009 | Cohort       | 27,227      | 45-73                    | Men and women, never-smokers | Snuff    | Fatal and non-fatal | 0.75 (0.3-1.8)  | Age, smoking, BMI, BP, diabetes, physical activity, occupation, marital status |
| Arefalk et al, 2012   | Cohort       | 119,491     | >30                      | Men    | Snu         | Non-fatal | ULSAM 2.08 (1.03-4.22) CWC 1.28 (1.00-1.64) | Age, smoking, hypertension |
| Author/year      | Study design | Sample size | Age of participants (yr) | Gender | Type of SLT               | Outcome studied | ORs/RRs (95% CI)                        | Confounders adjusted                                                                 |
|------------------|--------------|-------------|--------------------------|--------|---------------------------|-----------------|----------------------------------------|--------------------------------------------------------------------------------------|
| **American Region**                                                                                                                                   |
| Accortt et al., 2002<sup>24</sup> | Cohort       | 12,451      | 25-74                    | Men and women, never-smokers | SLT not specified | Fatal | Men 0.60 (0.3-1.2)                     | Age, smoking, BMI, systolic BP, cholesterol, alcohol intake, gender, socioeconomic status |
| Henley et al., 2005<sup>23</sup> | Cohort       | 77,407 CPS I | >30                      | Men, never-smokers            | Chewing tobacco/snuff | Fatal | CPS I cohort 1.12 (1.03-1.21)          | Age, smoking, BMI, alcohol intake, education, exercise, fruit and vegetable intake, aspirin use |
|                  |              | 113,970 CPS II |                           |        |                           |                 | CPS II cohort 1.26 (1.08-1.47)         |                                                                                       |
| Timberlake et al, 2017<sup>26</sup> | Cohort       | 348,282     | >30                      | Men and women, never-smokers | SLT               | Fatal | 1.24 (1.05-1.46) current user         | Age, gender, race, education, family income, smoking                                 |
| **Eastern Mediterranean Region**                                                                                                                       |
| Alexander 2013<sup>27</sup> | Case control | Cases 6051   | Adults                   | Men and women, never-smokers | Naswar/chewing tobacco | Non-fatal | Naswar 1.46 (1.2-1.77) Chewing 1.71 (1.46-2.0) | Age, sex, recruitment centre, ethnicity, LDL cholesterol, waist-hip ratio, smoking, BP, diabetes |
| Islami et al, 2013<sup>28</sup> | Cross-sectional | 50045      | 40-75                    | Men and women                | Nass chewing     | Non-fatal | 0.85 (0.73-1.00)                      | Age, sex, ethnicity, residence, education, wealth, physical activity, BMI, hypertension, smoking, self-reported diabetes |
| Etemadi et al, 2017<sup>29</sup> | Cohort       | 50,045      | 40-75                    | Men and women                | Nass chewing     | Fatal | 1.16 (0.87-1.55)                      | Age, SES, Residence, Education, Smoking                                                |
| **South East Asian Region**                                                                                                                          |
| Gupta et al, 2005<sup>30</sup> | Cohort       | 97,244      | >35                      | Men and women, exclusive SLT users | Mishri and others | Fatal | Men 0.89 (0.75-1.05) Women 1.25 (1.05-1.49) | Age, smoking, education                                                                    |

*Contd...*
Studies from European region (EUR): Seven of 11 studies from this Region were cohort while four were case control. Except for the study by Janzon and Hedblad, all other reports included only male SLT users in the adult age range. The predominant type of SLT consumed was snuff (eight studies) or snus (two studies), while the study by Bolinder et al did not specify the SLT product used by study participants. The outcome evaluated in one study was fatal CHD while in four others, separate results were given for fatal as well as non-fatal CHD. In five studies, both fatal and non-fatal outcomes were included, though separate results were not given. One study evaluated the risk of first hospitalization due to heart failure.

Of the 11 studies, two reported the significant positive association of fatal CHD with SLT use. The other three studies reporting on fatal CHD did not find a similar association. The rest of the studies also did not report a significantly increased risk of CHD in SLT users. The study assessing the association of SLT and heart failure demonstrated a higher risk of failure in current snus users.

Smoking was adjusted in eight studies (including three with positive association). However, other confounding risk factors for CHD such as body mass index, BP, diabetes and cholesterol levels were adjusted in fewer studies.

Studies from South-East Asia Region (SEAR): Majority (four of five) of the studies were case-control design and included both males and females though gender-wise results were provided in only three studies. SLT product included in these studies was predominantly chewable tobacco in the form of mishri, jarda, sada pata, gul and others. Three studies evaluated non-fatal outcome while two included only fatal CHD. Two studies showed an overall significant positive association between SLT use and non-fatal CHD. Two studies reported significantly increased risk of fatal CHD in female SLT users only. Smoking was adjusted in four out of five studies while other risk factors were adjusted in fewer studies.

Studies from American Region (AMR) and Eastern Mediterranean Region (EMR): All the three reports from AMR were cohort studies evaluating only fatal outcome. Two studies included both males and females while the other had only male participants. All the studies adjusted for smoking while two adjusted for body mass index (BMI). In contrast, one study from

### Table: Studies from Various Regions

| Author/year                          | Study design | Sample size          | Age of participants (yr) | Gender                  | Type of SLT       | Outcome studied | ORs/RRs (95% CI)                       | Confounders adjusted                  |
|--------------------------------------|--------------|----------------------|--------------------------|-------------------------|-------------------|-----------------|---------------------------------------|---------------------------------------|
| Rahman and Zaman 2008               | Case control | Cases 69 Controls 138| 20-49                    | Men and women           | Dried tobacco leaves | Non-fatal      | Males 1.60 (0.3-7.5); Females 4.50 (1.2-16.7) | Age, smoking, BP                         |
| Rahman et al, 2012                  | Case control | Cases 302 Controls 1510 | 40-75                    | Men and women, never-smokers | Jarda, sada pata, gul | Non-fatal      | 0.80 (0.51-1.24)                     | Age, smoking, BP, diabetes, acute psychosocial stress |
| Ram and Trivedi 2012                | Case control | Cases 135 Controls 135 | 31-80                    | Not mentioned           | SLT not specified | Non-fatal      | 1.77 (1.04-3.01)                     | Age                                   |
| Gajalakshmi and Kanimozhi 2015      | Case control | Cases 22,000 Controls 429,000 | 35-69                    | Men and Women, Never smokers | Chewing tobacco      | Fatal          | Urban men 1.0 (0.9-1.2); Rural men 1.0 (0.9-1.2); Urban women 1.0 (0.9-1.1); Rural women 1.2 (1.1-1.4) | Age, smoking, gender, education, alcohol |
| Teo et al, 2006                     | Case control | Cases 12,461 Controls 14,637 | 44-75                    | Men and women (chewing tobacco alone) | Chewing               | Non-fatal      | 2.23 (1.41-3.52)                     | Age, smoking, BP, diabetes, obesity, exercise, diet |

BP, blood pressure; BMI, body mass index; SES, socioeconomic status; ULSAM, Uppsala Longitudinal Study of Adult Men; CWC, Construction Workers’ Cohort; ORs, odds ratios; RRs, risk ratios; CPS, Cancer Prevention Study
EMR was cohort29, one was case-control32 and the third was cross-sectional28. All studies included males and females using naswar/nass or chewing tobacco. The outcome evaluated was fatal in one study29 and non-fatal in other27,28. Smoking was adjusted in all studies; however, other factors such as BP, diabetes and cholesterol were adjusted in only one study27.

Of the studies from AMR, two reported significantly higher risk of fatal CHD in SLT users25,34 while the third study did not find an association between the two24. The results in studies from EMR were also variable (significant in one27 and not in other two28,29).

The landmark INTERHEART case-control study35 reported a significantly higher risk of non-fatal CHD in tobacco chewers [odds ratio (OR) 2.23, 95% confidence interval (CI) 1.41-3.52]. The study adjusted for factors such as smoking, BP, diabetes and obesity.

**Smokeless tobacco (SLT) and stroke**: Fourteen studies were retrieved on the topic of risk of stroke in SLT users. Seven were reported from EUR14,20,22,36-38, three each from SEAR30,34,39 and AMR24-26 and one from EMR29 (Table II). Majority (10) were cohort studies, one nested case-control and two case-control design. Six of seven EUR studies included only males while one included both genders. Only fatal stroke was reported in six studies while non-fatal outcome was reported in three. Four studies included both outcomes, though only two of these provided separate results for fatal stroke.

All the EUR studies failed to report a significant positive association between SLT use and stroke. One study from SEAR and one from AMR demonstrated a significantly higher risk of fatal stroke in SLT users25,34. Most of the studies (13 of 14) adjusted for smoking as a confounding factor or included never-smoking participants. Only five studies considered HTN as a confounding variable21,22,24,39 while diabetes was adjusted in four studies14,21,22,39.

**Hypertension in smokeless tobacco users**: In contrast to CHD and stroke, a majority of the included studies on the participant of risk of HTN in SLT users were reported from SEAR (eight from India10,11,40-45 and two from Bangladesh36,47). Two studies were retrieved from EUR48,49 and one each from AFR50 and EMR51. Most of the studies were cross-sectional and all included adult participants (Table III). Ten of the 14 studies included only men while one had only female participants. In five studies, participants used chewing tobacco, three focused on snuff while the rest six studies did not specify the SLT product used.

Six of 14 studies demonstrated a significant positive association between SLT use and HTN. One study reported significant risk of diastolic HTN in SLT users but not for systolic HTN. Another study found a significant risk of diastolic HTN in SLT users of all age groups (16-65 yr) while systolic HTN was higher in the age range of 46-65 yr49. The remaining six studies did not find any significant association between HTN and SLT use. Only four studies adjusted smoking as confounding variable while three considered salt intake as a confounder.

**Discussion**

Although SLT has been causatively linked to adverse health effects including addiction, cancers of oral cavity, oesophagus and pancreas and poor reproductive outcomes, its association with cardiovascular diseases has not been accepted widely52. This has mainly been due to the conflicting reports on this topic from various Regions and countries4,7-9. Meta-analyses conducted so far on the participant of SLT use and cardiovascular risk have included CHD or MI and stroke4,7-9. None of these included the assessment of risk of HTN in SLT users. In the present review all the three cardiovascular outcomes were included in SLT users.

**Smokeless tobacco use and heart disease**: Heart disease was the most frequently studied cardiovascular outcome with maximum number of studies. Marked regional variation was identified in the results on the association of SLT use with heart disease. Majority of the studies from EUR did not report significantly increased risk of CHD in SLT users while studies from SEAR30,31,34 showed positive association between the two. This regional difference has been attributed to the variation in chemical composition of the products used in these Regions4.

Although European studies do not support the association of CHD with SLT, there have been reports of higher mortality rate due to CHD in individuals switching from cigarettes to spit tobacco [hazard ratio (HR) 1.13, 95% CI 1.00-1.29] in multivariate model adjusted for the duration and number of cigarettes smoked per day before switching apart from other confounding factors53. In this context, reduction of post-MI mortality risk in snus quitters as opposed to continuing snus users (HR 0.57, 95% CI 0.32-1.02) has also been demonstrated54. Such reports support the hypothesis of deleterious effects of SLT products on
Table II. Studies evaluating smokeless tobacco (SLT) and stroke included in the review

| Author/year                  | Type of study | Sample size | Age range | Gender | Type of SLT | Outcome studied | OR/RR (95% CI) | Confounders adjusted                                                                 |
|------------------------------|---------------|-------------|-----------|--------|-------------|-----------------|----------------|-------------------------------------------------------------------------------------|
| **European Region**          |               |             |           |        |             |                 |                |                                                                                     |
| Bolinder et al, 1994        | Cohort        | 135036      | >35 yr    | Men    | ND          | Fatal           | 35-54 yr 1.9 (0.6-5.7) 55-65 yr 1.2 (0.7-1.8) | Smoking, age, area of domicile, BP, previous cardiac symptoms, DM, BMI                |
| Asplund et al, 2003          | Nested case control | Cases 276 | 25-74 | Men | Snuff | Both | 0.87 (0.41-1.83) | Smoking, BP, education, marital status, DM, cholesterol |
| Haglund et al, 2007         | Cohort        | 5002        | 16-74     | Men    | Snuff | Both | IR 1.07 (0.65-1.77) MR 1.01 (0.35-2.92) | Age, SES, residence, self-reported health, longstanding illnesses, physical activity |
| Hergens et al, 2008         | Cohort        | 118465      | ND        | Men    | Snuff | Both | Non-fatal 1.02 (0.91-1.14) Fatal 1.38 (0.99-1.91) | Age, smoking, BMI, residence |
| Janzon and Hedblad, 2009     | Cohort        | 27227       | 45-73     | Men and women | Snuff | Both | 0.59 (0.2-1.5) | Age, BMI, smoking, DM, HTN, activity, marital status, occupation |
| Hannsson et al, 2009         | Cohort        | 16642       | >40 yr    | Men    | Snus | Both | 1.18 (0.67-2.08) | Age, DM, BP, cholesterol, smoking |
| Hannsson et al, 2014         | Pooled cohort | 130485      | Mean age 68 | Men, never-smokers | Snus | Both | 1.04 (0.92-1.17) Overall 1.32 (1.08-1.61) Fatal | Age, BMI, smoking |
| **American Region**          |               |             |           |        |             |                 |                |                                                                                     |
| Accortt et al, 2002          | Cohort        | 6805        | 45-75     | Men and women | ND | Fatal | Men 0.7 (0.2-2) Women 1 (0.3-2.9) | Age, race, poverty index, alcohol, exercise, fruit/vegetable intake, systolic BP, smoking |
| Henley et al, 2005           | Cohort        | CPS I 7745  | >30 yr    | Men | Both | Fatal | CPS I 1.46 (1.3-1.64) CPS II 1.4 (1.1-1.79) | Age, race, education, BMI, exercise, alcohol, fruit, aspirin use, employment status, fat consumption |
| Timberlake et al, 2017       | Cohort        | 349282      | >30 yr    | Men and SLT | never-smokers | Fatal | 0.92 (0.67-0.27) | Age, gender, race, education, family income, smoking |
| **South East Asian Region**  |               |             |           |        |             |                 |                |                                                                                     |
| Gupta et al, 2005            | Cohort        | 97,244      | >35 yr    | Men and women | Chewing | Fatal | Men 1.32 (0.94-1.84) Women 1.15 (0.84-1.59) | Age, education, smoking |
| Agashe and Gawde, 2010       | Case control  | Cases 80    | Mean 61.8 yr | Men | Chewing | Non-fatal | 1.5 (0.8-2.79) | HTN, alcohol, DM, smoking |
| Gajalakshmi and Kanimozhi, 2015 | Case control  | Cases 22000 | 35-69 yr | Men and women | Chewing | Fatal | Urban men 1.1 (0.7-1.7) Rural men 2.2 (1.6-3.0) Urban women 1.3 (1.1-1.7) Rural women 1.3 (1.0-1.6) | Age, education, smoking, alcohol |
| **Eastern Mediterranean Region** | Cohort        | 1393        | 40-75     | Men and women | Nass | Fatal | 0.98 (0.65-1.47) | Age, SES, residence, education, smoking |

BP, blood pressure; DM, diabetes mellitus; BMI, body mass index; HTN, hypertension; IR, incidence ratio; MR, mortality ratio
Table III. Study characteristics of included reports on risk of hypertension in smokeless tobacco (SLT) users

| Author/year | Study design | Sample size | Age (yr) | Gender | SLT type | OR/RR (95% CI) | Confounder adjusted |
|-------------|--------------|-------------|----------|--------|----------|----------------|---------------------|
| **European Region** | | | | | | | |
| Bolinder et al, 1992<sup>10</sup> | Cross-sectional | 97586 | 16-65 | Men | SLT | Diastolic BP | Not mentioned |
| | | | | | | 16-35 yr 1.3 (1.0-1.7) | |
| | | | | | | 36-45 yr 1.3 (1.0-1.6) | |
| | | | | | | 46-55 yr 1.8 (1.5-2.1) | |
| | | | | | | 56-65 yr 1.3 (1.1-1.4) | |
| | | | | | | Systolic BP | |
| | | | | | | 16-35 yr 1.0 (0.5-1.7) | |
| | | | | | | 36-45 yr 1.3 (0.8-2.1) | |
| | | | | | | 46-55 yr 1.7 (1.3-2.1) | |
| | | | | | | 56-65 yr 1.2 (1.1-1.4) | |
| Hergens et al, 2008<sup>8</sup> | Cohort | 120930 | Adults | Men | Snuff | 1.25 (1.16-1.35) | Age, BMI, residence, smoking |
| Hazarika et al, 2004<sup>40</sup> | Pop based | 3180 | >30 | Men and women | Chewing | 1.1 (0.94-1.3) | Not mentioned |
| Gupta et al, 2007<sup>31</sup> | Case control | 200 cases, 200 controls | 46.8 mean | Men and women | Chewing | Systolic 1.76 (1.14-2.7) | Not mentioned |
| Pandey et al, 2009<sup>41</sup> | Cross sectional | 443 | 35.4 mean | Men | SLT | Systolic 1.4 (0.8-2.7) | Not mentioned |
| Kannan & Satyamoorthy, 2009<sup>42</sup> | Cross sectional | 750 | >30 | Men and women | Chewing | 1.5 (0.99-2.27) | Not mentioned |
| Bhadoria et al, 2014<sup>43</sup> | Cross sectional | 939 | >20 | Men and women | Chewing | Urban 6.8 (2.8-16.2) | Age, family history, salt, smoking, physical, BMI |
| Sen et al, 2015<sup>11</sup> | Survey | 916 | 20-60 | Men | SLT | Rural 2.1 (1.16-3.53) | Age, SBP, BMI, Family history |
| Islam et al, 2015<sup>45</sup> | Cross sectional | 730 | >25 | Men and women | SLT | 3.61 (2.33-4.14) | Age, sex, education, marital, employment, income, extra salt, activity, family history, smoking |
| Khanam et al, 2015<sup>47</sup> | Cross sectional | 6094 | >25 | Men and women | Chewing | 0.89 (0.74-1.07) | Age, sex, education, BMI, smoking, physical |
| Ismail et al, 2016<sup>44</sup> | Community based | 600 | 39.8 mean | Men and women | SLT | 2.12 (1.4-3.2) | Not mentioned |
| Choudhury & Ojah, 2017<sup>46</sup> | Cross sectional | 870 | >30 | Men and women | SLT | 1.13 (0.77-1.65) | Not mentioned |
| **African Region** | | | | | | | |
| Ayo-Yusuf & Omole 2008<sup>40</sup> | Cross sectional | 4092 | 49.2 mean | Women | Snuff | Up to eight times 1.01 (0.75-1.96) | | |
| | | | | | | >8 times 2.07 (0.89-4.82) | | |
| **Eastern Mediterranean Region** | | | | | | | |
| Shah et al, 2001<sup>31</sup> | Cross sectional | 4203 | >18 | Men and women | Snuff | 1.59 (1.31-1.92) | Not mentioned |

SBP, systolic blood pressure
cardiac functions independently of concurrent or past smoking status. A recently published meta-analysis on the association of SLT use with CHD from our group showed significantly higher risk of fatal CHD in SLT users (1.10, 95% CI 0.00-1.27). Regional variation was also reported in this analysis with higher risk for European users compared to other Regions.

The effect of SLT over cardiovascular risk factors has also been evaluated. Gutka chewers were found to have a significant higher resting heart rate and lower delta heart rate (the difference between maximal heart rate and resting rate) immediately after chewing gutka. Delta heart rate has been reported to be a risk factor for cardiovascular mortality independent of age, smoking, systolic BP, serum cholesterol and triglyceride level and physical fitness. Others have reported greater prevalence of risk factors such as obesity, tachycardia at rest, HTN, high total and low-density lipoprotein (LDL) cholesterol and changes on electrocardiogram in SLT users. A study from Turkey has found impairment in left atrial mechanical function and prolongation of atrial electromechanical coupling intervals in users of maras powder and suggested these changes to be markers of tendency for atrial fibrillation. Altered lipid profile with lower serum high-density lipoprotein cholesterol and significantly increased total cholesterol, LDL cholesterol and triglycerides have been demonstrated with SLT products such as naswar and chewing tobacco. However, these results and their implications for cardiovascular disease need to be confirmed in further studies.

**Smokeless tobacco use and cerebrovascular disease:** Cerebrovascular disease, especially stroke, is a global health problem and a leading cause of disability and death. Smoking has been incriminated as a major risk factor in causation of stroke. However, the association with SLT is similar to that for CHD with conflicting results in studies from various Regions and within a particular Region as well. Majority of the European studies did not report any significant positive association between SLT and stroke, though Hergens et al. found a significant risk of fatal ischaemic stroke in SLT users, but the same was not detected for haemorrhagic stroke. This difference in risk according to subtype of stroke could well be explained on the basis of differing aetiological mechanisms of haemorrhagic and ischaemic stroke.

An earlier meta-analysis demonstrated that 12.8 per cent higher risk of stroke in current users of SLT especially for studies from the United States but not for Swedish users. The risk of fatal stroke was also found to be higher in SLT users in this analysis. Vidyasagar et al. found no overall association of SLT use and non-fatal stroke while risk of fatal events was 13.9 per cent higher in SLT users. Similar results were reported in another meta-analysis of cause-specific mortality in SLT users. One study evaluated the risk of subarachnoid haemorrhage (SAH) in smokers and snuff users. The authors found 2.5 times higher risk of SAH in smokers; however, consumption of snuff did not impart a similar risk ratio (relative risk 0.48, 95% CI 0.17-1.30).

In addition to the studies included in this review, two other reports that evaluated risk of cardiovascular disease (including both MI and stroke) in SLT users were found. These did not provide separate results for the outcomes and hence, were not included in the present review. One of these studies found an excess risk of cardiovascular disease-related disability pension in the age group of 56-65 yr (OR 1.5, 95% CI 1.1-1.9). The other study reported a 1.27-fold greater incidence of cardiovascular diseases in current SLT users (95% CI 1.06-1.52) compared to nonusers, and this risk was independent of demographic, socio-economic and other tobacco-related variables. Hence, there appears to be a significant positive association between SLT use and fatal stroke.

**Hypertension and smokeless tobacco use:** HTN, an important risk factor for death and morbidity globally, is one of the major causes of ischaemic heart disease, stroke and heart failure. For developing countries like India, rule of halves, i.e., half of the hypertensives are undetected, half of those detected are untreated and half of treated are not well controlled is still valid and poses a significant challenge for control of HTN and incident cardiovascular diseases.

Cigarette smoking has been shown to cause an acute elevation of BP and heart rate due to effect of nicotine on sympathetic nervous system. However, chronic effect of smoking on BP has not been effectively established due to conflicting reports. Thy et al. reported a dose-response relationship between smoking and HTN while others have found a lower BP in smokers compared to non-smokers. The causal association of SLT with HTN is also similarly debated with approximately half of the studies reporting a significant positive association between the two parameters and the rest not corroborating.
The main strengths of this studies from African and Western Pacific Regions in confounder adjustment. There is also paucity of particular, studies from SEAR were found to be poor level of physical activity, alcohol intake and stress. In SLT users did not adjust for excess salt intake, obesity, MI. Similarly, most of the studies on the risk of HTN in considered in only a few studies evaluating CHD or serum cholesterol levels and physical activity were not adjusted universally in all studies. For instance, risk factors such as HTN, BMI, factors were not adjusted universally in all studies. Although smoking was adjusted as a confounder or study participants included only never-smokers in majority of the reports, other disease-specific risk factors were not adjusted universally in all studies. For instance, risk factors such as HTN, BMI, serum cholesterol levels and physical activity were considered in only a few studies evaluating CHD or MI. Similarly, most of the studies on the risk of HTN in SLT users did not adjust for excess salt intake, obesity, level of physical activity, alcohol intake and stress. In particular, studies from SEAR were found to be poor in confounder adjustment. There is also paucity of studies from African and Western Pacific Regions in the current literature in spite of high prevalence of SLT use in some areas of these Regions. Since the present review was not aimed for a quantitative analysis of risk estimate, it was not possible to comment conclusively on the risk association of cardiovascular diseases with SLT use. However, the available literature does indicate a significantly higher risk of fatal cardiac and cerebrovascular events in SLT users.

Conclusion & way forward

To elucidate a clear view of the cardiovascular risk associated with SLT use, future well-designed studies, preferably multicountry with uniformity in case definition, study methods and relevant confounder adjustments, are imperative. Since regional variability in cardiovascular effects has been demonstrated due to differences in product composition, studies from all regions are required for definitive opinion on the participant. Clarity on the issue of association of cardiovascular disease with SLT would assist the policymakers to include mandatory SLT cessation advice for patients presenting with one of these diseases or their risk factors.

Financial support & sponsorship: None.

Conflicts of Interest: None.

References

1. Rahman MA. A systematic review of epidemiological studies on the association between smokeless tobacco use and coronary heart disease. J Public Heal Epidemiol 2011; 3 : 593-603.
2. Sinha D, Agarwal N, Gupta P. Prevalence of smokeless tobacco use and number of users in 121 Countries. Br J Med Med Res 2015; 9 : 1-20.
3. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2004; Lyon, France: v.89.
4. Vidyasagar AL, Siddiqi K, Kanaan M. Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23 : 1970-81.
5. Rahman MA, Mahmood MA, Spurrier N, Rahman M, Choudhury SR, Leeder S, et al. Why do bangladeshi people use smokeless tobacco products? Asia Pac J Public Health 2015; 27 : NP2197-209.
6. Adedigba MA, Aransiola J, Arobieke RI, Adewole O, Oyelami T. Between traditions and health: Beliefs and perceptions of health effects of smokeless tobacco among selected users in Nigeria. Subst Use Misuse 2018; 53 : 565-73.
7. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: Systematic review with meta-analysis. BMJ 2009; 339 : b3060.
8. Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal N, Parascandola M, et al. Global burden of all-cause and cause-specific mortality due to smokeless tobacco use: Systematic review and meta-analysis. *Tob Control* 2018; 27 : 35-42.

9. Gupta R, Gupta S, Sharma S, Sinha DN, Mehrotra R. Risk of coronary heart disease among smokeless tobacco users: Results of systematic review and meta-analysis of global data. *Nicotine Tob Res* 2018 Jan 9. doi: 10.1093/ntr/nty002. [Epub ahead of print].

10. Bhadoria AS, Kasar PK, Toppo NA, Bhadoria P, Pradhan S, Kabirpanthi V, et al. Prevalence of hypertension and associated cardiovascular risk factors in central India. *J Family Community Med* 2014; 21 : 29-38.

11. Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal N, Parascandola M, et al. Global burden of all-cause and cause-specific mortality due to smokeless tobacco use: Systematic review and meta-analysis. *Tob Control* 2018; 27 : 35-42.

12. Hergens MP, Alfredsson L, Bolinder G, de Faire U. Swedish moist snuff and myocardial infarction: A 12-year follow-up study. *Am J Public Health* 1999; 89 : 399-404.

13. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: A population-based study in middle-aged men. *J Am Coll Cardiol* 1999; 34 : 1784-90.

14. Hergens MP, Ahlbom A, Andersson T, Pershagen G. Swedish moist snuff and myocardial infarction among men. *Epidemiology* 2005; 16 : 12-6.

15. Hergens MP, Alfredsson L, Bolinder G, Lambe M, Pershagen G, Ye W. Long-term use of Swedish moist snuff and the risk of myocardial infarction among men. *J Intern Med* 2007; 262 : 351-9.

16. Wernberg P, Eliasson M, Hallmans G, Johansson L, Boman K, Jansson JH. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. *J Intern Med* 2007; 262 : 360-7.

17. Haglund B, Eliasson M, Stenbeck M, Rosén M. Is moist snuff use associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden. *Scand J Public Health* 2007; 35 : 618-22.

18. Hansson J, Pedersen NL, Galanti MR, Andersson T, Ahlbom A, Hallqvist J, et al. Use of snus and risk for cardiovascular disease: Results from the Swedish Twin Registry. *J Intern Med* 2009; 265 : 717-24.

19. Janzon E, Hedblad B. Swedish snuff and incidence of cardiovascular disease. A population-based cohort study. *BMC Cardiovasc Disord* 2009; 9 : 21.

20. Arefalk G, Hergens MP, Ingelsson E, Arnlov J, Michaéllson K, Lind L, et al. Smokeless tobacco (snus) and risk of heart failure: Results from two Swedish cohorts. *Europ J Prev Cardiol* 2012; 19 : 1120-7.

21. Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. *Am J Epidemiol* 2002; 156 : 730-7.

22. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United states). *Cancer Causes Control* 2005; 16 : 347-58.

23. Alexander M. Tobacco use and the risk of cardiovascular diseases in developed and developing countries. Cambridge: University of Cambridge; 2013.

24. Islam F, Poursamans A, Vedanthan R, Poustchi H, Kamanger F, Golozar A, et al. Smoking water-pipe, chewing nass and prevalence of heart disease: A cross-sectional analysis of baseline data from the Golestan Cohort Study, Iran. *Heart* 2013; 99 : 272-8.

25. Rahman M, Zaman MM. Smoking and smokeless tobacco consumption: Possible risk factors for coronary heart disease among young patients attending a tertiary care cardiac hospital in Bangladesh. *Public Health* 2008; 122 : 1331-8.

26. Rahman MA, Spurrier N, Mahmood MA, Rahman M, Choudhury SR, Leeder S. Is there any association between use of smokeless tobacco products and coronary heart disease in Bangladesh? *PLoS One* 2012; 7 : e30584.

27. Ram RV, Trivedi A. Smoking, smokeless tobacco consumption & coronary artery disease – A case control study. *Natl J Community Med* 2012; 3 : 264-8.

28. Gajalakshmi V, Kanimozi V. Tobacco chewing and adult mortality: A case-control analysis of 22,000 cases and 429,000 controls, never smoking tobacco and never drinking alcohol, in South India. *Asian Pac J Cancer Prev* 2015; 16 : 1201-6.

29. Teo KK, Oumpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. *Lancet* 2006; 368 : 647-58.
36. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: A nested case-control study. *Stroke* 2003; 34 : 1754-9.

37. Hergens MP, Lambe M, Pershagen G, Terent A, Ye W. Smokeless tobacco and the risk of stroke. *Epidemiology* 2008; 19 : 794-9.

38. Hansson J, Galanti MR, Hergens MP, Fredlund P, Ahlbom A, Alfredsson L, *et al.* Snus (Swedish smokeless tobacco) use and risk of stroke: Pooled analyses of incidence and survival. *J Intern Med* 2014; 276 : 87-95.

39. Agashe A, Gawde N. Stroke and the use of smokeless tobacco – A case-control study. *Healthline* 2013; 4 : 13-8.

40. Hazarika NC, Narain K, Biswas D, Kalita HC, Mahanta J. Hypertension in the native rural population of Assam. *Nat Med J India* 2004; 17 : 300-4.

41. Gupta BK, Kaushik A, Panwar RB, Chaddha VS, Nayak KC, Singh VB, *et al.* Cardiovascular risk factors in tobacco-chewers: A controlled study. *J Assoc Physicians India* 2007; 55 : 27-31.

42. Kannan A, Satyamoorthy TS. An epidemiological study of hypertension in a rural household community. *Sri Ramachandra J Med* 2009; 2 : 9-13.

43. Pandey A, Patni N, Sarangi S, Singh M, Sharma K, Vellimana AK, *et al.* Association of exclusive smokeless tobacco consumption with hypertension in an adult male rural population of India. *Tob Induc Dis* 2009; 5 : 15.

44. Ismail IM, Kulkarni AG, Meundi AD, Amruth M. A community-based comparative study of prevalence and risk factors of hypertension among urban and rural populations in a coastal town of South India. *Sifa Med J* 2016; 3 : 41.

45. Choudhury SA, Ojaj A. A cross sectional study on hypertension and tobacco consumption in the rural adult population of Kamrup, Assam. *Int J Sci Res* 2017; 6 : 740-4.

46. Islam SM, Maimuddin A, Islam MS, Karim MA, Mou SZ, Arefin S, *et al.* Prevalence of risk factors for hypertension: A cross-sectional study in an urban area of Bangladesh. *Glob Cardiol Sci Pract* 2015; 2015 : 43.

47. Khanam MA, Lindeboom W, Razzaque A, Niessen L, Milton AH. Prevalence and determinants of prehypertension and hypertension among the adults in rural Bangladesh: Findings from a community-based study. *BMC Public Health* 2015; 15 : 203.

48. Hergens MP, Lambe M, Pershagen G, Ye W. Risk of hypertension amongst Swedish male snuff users: A prospective study. *J Intern Med* 2008; 264 : 187-94.

49. Bolinder GM, Ahlborg BO, Lindell JH. Use of smokeless tobacco: Blood pressure elevation and other health hazards found in a large-scale population survey. *J Intern Med* 1992; 232 : 327-34.

50. Ayo-Yusuf OA, Omole OB. Snuff use and the risk for hypertension among black South African women. *S Afr Fam Pract* 2008; 50 : 64-8.

51. Shah SM, Luby S, Rahbar M, Khan AW, McCormick JB. Hypertension and its determinants among adults in high mountain villages of the Northern areas of Pakistan. *J Hum Hypertens* 2001; 15 : 107-12.

52. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. *Lancet Oncol* 2008; 9 : 667-75.

53. Henley SJ, Connell CJ, Richter P, Husten C, Pechacek T, Calle EE, *et al.* Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. *Tob Control* 2007; 16 : 22-8.

54. Areffalk G, Hambraeus K, Lind L, Michaëllson K, Lindahl B, Sundström J. Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. *Circulation* 2014; 130 : 325-32.

55. Pakkala A, Ganashree CP, Raghvendra T. Cardiopulmonary efficiency in *gutta* chewers: An Indian study. *J Med Investig Pract* 2014; 9 : 74-8.

56. Sandvik L, Eriksen J, Ellestad M, Eriksen G, Thaulow E, Mundal R, *et al.* Heart rate increase and maximal heart rate during exercise as predictors of cardiovascular mortality: A 16-year follow-up study of 1960 healthy men. *Coron Artery Dis* 1995; 6 : 667-79.

57. Akcay A, Aydin MN, Acar G, Mese B, Çetin M, Akgungor M, *et al.* Evaluation of left atrial mechanical function and atrial conduction abnormalities in maras powder (smokeless tobacco) users and smokers. *Cardiovasc J Afr* 2015; 26 : 114-9.

58. Sajid F, Bano S. Effects of smokeless dipping tobacco (Naswar) consumption on antioxidant enzymes and lipid profile in its users. *Pak J Pharm Sci* 2015; 28 : 1829-33.

59. Khurana M, Sharma D, Khandelwal PD. Lipid profile in smokers and tobacco chewers – A comparative study. *J Assoc Physicians India* 2000; 48 : 895-7.

60. Shinton R, Beever G. Meta-analysis of relation between cigarette smoking, exercise, and mortality risk after myocardial infarction. *J Epidemiol Community Health* 1991; 45 : 229-32.

61. Shinton R, Beever G. Meta-analysis of relation between cigarette smoking, exercise, and mortality risk after myocardial infarction. *J Epidemiol Community Health* 1991; 45 : 229-32.

62. Shinton R. Lifelong exposures and the potential for stroke in men: A nested case-control study. *Stroke* 1991; 22 : 983-8.

63. Koskinen LO, Blomstedt PC. Smoking and non-smoking tobacco as risk factors in subarachnoid haemorrhage. *Acta Neurol Scand* 2006; 114 : 33-7.

64. Yatsuya H, Folsom AR; ARIC Investigators. Risk of incident cardiovascular disease among users of smokeless tobacco in the atherosclerosis risk in communities (ARIC) study. *Am J Epidemiol* 2010; 172 : 600-5.

65. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, *et al.* Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. *JAMA* 2002; 287 : 1003-10.

66. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., *et al.* Seventh report of the joint national...
committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension* 2003; 42: 1206-52.

67. Wilber JA, Barrow JG. Hypertension – A community problem. *Am J Med* 1972; 52: 653-63.

68. Deepa R, Shanthirani CS, Pradeepa R, Mohan V. Is the ‘rule of halves’ in hypertension still valid? – Evidence from the Chennai Urban Population Study. *J Assoc Physicians India* 2003; 51: 153-7.

69. Faizi N, Ahmad A, Khalique N, Shah MS, Khan MS, Maroof M. Existence of rule of halves in hypertension: an exploratory analysis in an Indian village. *Mater Sociomed* 2016; 28: 95-8.

70. Ilgenli TF, Akpinar O. Acute effects of smoking on right ventricular function. A tissue Doppler imaging study on healthy subjects. *Swiss Med Wkly* 2007; 137: 91-6.

71. Thuy AB, Blizzard L, Schmidt MD, Luc PH, Granger RH, Dwyer T. The association between smoking and hypertension in a population-based sample of Vietnamese men. *J Hypertens* 2010; 28: 245-50.

72. Berglund G, Wilhelmsen L. Factors related to blood pressure in a general population sample of Swedish men. *Acta Med Scand* 1975; 198: 291-8.

73. Wolk R, Shamsuzzaman AS, Svatikova A, Huyber CM, Huck C, Narkiewicz K, et al. Hemodynamic and autonomic effects of smokeless tobacco in healthy young men. *J Am Coll Cardiol* 2005; 45: 910-4.

74. Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of smokeless tobacco products on cardiovascular disease: Implications for policy, prevention, and treatment: A policy statement from the American Heart Association. *Circulation* 2010; 122: 1520-44.

75. Habib N, Rashid M, Begum U, Ahter N, Akhter D. Blood pressure parameters among smokers and smokeless tobacco users in a tertiary level hospital. *Med Today* 2013; 25: 28-31.

76. Bolinder G, de Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. *Am J Hypertens* 1998; 11: 1153-63.

For correspondence: Dr Ruchika Gupta, Division of Cytopathology, ICMR-National Institute of Cancer Prevention & Research, I-7, Sector-39, Noida 201 301, Uttar Pradesh, India
e-mail: ruchika257@yahoo.com